Vysis seeks European approval for breast cancer gene test
This article was originally published in Clinica
Vysis has taken the first step in its bid to market its test for the HER-2 breast cancer gene in Europe. The company has filed an application to register the test with the Agence du Medicament in France, which unlike most of the other European authorities, requires premarket approval for such tests. Once approved in France, the company says it will be able to market it in most of the other European countries without further approval.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.